David M. Jablons, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
David M. Jablons, MD

Professor in Residence, Department of Surgery, UCSF
Ada Distinguished Professorship in Thoracic Oncology, UCSF

Phone: (415) 885-3882 (appts)
Box 1724, UCSF
San Francisco, CA 94143-1724

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

I am the Ada Distinguished Professor in Thoracic Oncology and Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology at the University of California, San Francisco (UCSF). I am also Chief of General Thoracic Surgery, Program Leader of the Thoracic Oncology Program (TOP), and Director of the Thoracic Oncology Laboratory at UCSF. I oversee a thriving bench-to-bedside program at the UCSF Helen Diller Comprehensive Cancer, comprised of thoracic surgeons, thoracic oncologists, pulmonologists, radiation oncologists, and an array of other specialists.
The Thoracic Oncology lab utilizes state-of-the-art technology such as as next-generation sequencing (NGS), synthetic chemistry, and 3D-computer simulation for assessing drug efficacy. The TOP currently offers patients a broad menu of clinical trials, testing the most promising molecularly targeted agents. In 2005, I was awarded an NIH R01 grant to investigate the role of Wnt signaling in mesothelioma, and was awarded another R01 grant in 2008 to study the role of inflammation in lung carcinogenesis. The Thoracic Oncology lab has several areas of focus including molecular therapeutics, molecular diagnostics, systems biology, systems genetics, and bench-to-bedside drug discovery. The Thoracic Oncology Lab houses one of the largest thoracic tissue bank repositories in the US, with specimens for more than 1,300 patients including fresh/frozen matched tissue (tumor, normal, serum, pbmc) for lung cancer, mesothelioma, and other cancers.
I have been a pioneer in the field of molecular diagnostics, as part of a team that developed a multi-gene diagnostic assay identifying patients at risk for recurrence of early-stage non-small-cell lung cancer. I am also a co-investigator on several other grants as part of collaborations with lead PIs in other labs: (1) Development of new immunotherapy-based drugs for the treatment of lung cancer by isolating resident immune cells in lung tumor tissue to assess the adaptive immune response; (2) Investigation of the mechanism of the KMD5A protein in rendering NSCLC resistant to EGFR TKI therapy; and (3) Investigation of the role of genetic variation in TGF-beta overactivation in COPD.

Education

Yale College, BA, 1975-79, American Literature
Albany Medical Col. of Union U, MD, 1979-84
Naval Hospital, Intern, 1984-85, Surgery
Tufts University, Resident, 1985-86, Surgery
National Cancer Institute, National Institutes of Health, Fellow, 1986-89, Surgical Oncology
Tufts University, 1989-91, Surgery
Brigham & Women's Hospital, Fellow, 1992-92, Lung Transplantation
Cornell University Medical Center, Fellow, 1991-93, Surgery


Professional Experience

  • 1993-95
    Naval Medical Center, Attending, Cardiothoracic Surgery
  • 1994-95
    University of California, San Francisco School of Medicine, Assistant Clinical Professor, Cardiothoracic Surgery
  • 1995-00
    University of California, San Francisco School of Medicine, Assistant Professor, Cardiothoracic Surgery
  • 2000-04
    University of California, San Francisco School of Medicine, Associate Professor, Cardiothoracic Surgery
  • 2004-present
    University of California, San Francisco School of Medicine, Professor, Cardiothoracic Surgery
  • 2007-present
    University of California, San Francisco School of Medicine, Ada Distinguished Professor of Thoracic Oncology Surgery
  • 1986-89
    Fleet Hospital, Lieutenant, Medical Corps, USNR Staff Surgeon
  • 1989-91
    Fleet Hospital, Lieutenant Commander, Medical Corps,USNR Staff Surgeon
  • 1991-93
    Fleet Hospital, Lieutenant Commander, Medical Corps,USNR Staff Surgeon
  • 1997-present
    UCSF Medical Center, Chief, Section of General Thoracic Surgery

Selected Publications

  1. Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Ther Clin Risk Manag. 2016; 12:807-16.
    View on PubMed
  2. Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer. PLoS One. 2016; 11(2):e0148911.
    View on PubMed
  3. Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 2016 Jan 27.
    View on PubMed
  4. Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Hsieh MJ, Lin YC, Yang CT, Liu ST, Tsai YH. Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. Oncol Rep. 2015 Dec; 34(6):3187-95.
    View on PubMed
  5. Yang YL, Ni J, Hsu PC, Mao JH, Hsieh D, Xu A, Chan G, Au A, Xu Z, Jablons DM, You L. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. J Cell Mol Med. 2015 Oct; 19(10):2385-96.
    View on PubMed
  6. Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLoS One. 2015; 10(7):e0132134.
    View on PubMed
  7. Wang Y, Xu Z, Mao JH, Hsieh D, Au A, Jablons DM, Li H, You L. PR-Set7 is Degraded in a Conditional Cul4A Transgenic Mouse Model of Lung Cancer. Zhongguo Fei Ai Za Zhi. 2015 Jun 20; 18(6):345-50.
    View on PubMed
  8. Cox JC, Jablons DM. Operative and Perioperative Pulmonary Emboli. Thorac Surg Clin. 2015 Aug; 25(3):289-99.
    View on PubMed
  9. Wang Y, Xu Z, Mao JH, Hung MS, Hsieh D, Au A, Jablons DM, You L. Analysis of lung tumor initiation and progression in transgenic mice for Cre-inducible overexpression of Cul4A gene. Thorac Cancer. 2015 Jul; 6(4):480-7.
    View on PubMed
  10. Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL. Transforming Growth Factor-ß and Interleukin-1ß Signaling Pathways Converge on the Chemokine CCL20 Promoter. J Biol Chem. 2015 Jun 5; 290(23):14717-28.
    View on PubMed
  11. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. NF-?B-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Rep. 2015 Apr 7; 11(1):98-110.
    View on PubMed
  12. Letteboer TG, Benzinou M, Merrick CB, Quigley DA, Zhau K, Kim IJ, To MD, Jablons DM, van Amstel JK, Westermann CJ, Giraud S, Dupuis-Girod S, Lesca G, Berg JH, Balmain A, Akhurst RJ. Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Front Genet. 2015; 6:67.
    View on PubMed
  13. You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget. 2015 Feb 28; 6(6):4357-68.
    View on PubMed
  14. Hirata T, Zheng Q, Chen Z, Kinoshita H, Okamoto J, Kratz J, Li H, Lui N, Do H, Cheng T, Tseng HH, Koizumi K, Shimizu K, Zhou HM, Jablons D, He B. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma. Oncol Rep. 2015 Apr; 33(4):2052-60.
    View on PubMed
  15. Woodard GA, Jablons DM. The Latest in Surgical Management of Stage IIIA Non-Small Cell Lung Cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling. Am Soc Clin Oncol Educ Book. 2015; 35:e435-41.
    View on PubMed
  16. Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang LT, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. CK2a, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 2014; 33(1):93.
    View on PubMed
  17. Mo ML, Ma J, Chen Z, Wei B, Li H, Zhou Y, Shi H, Tolani B, Jin JQ, Tseng HH, Shen D, Zhan Y, Li J, Jablons DM, Zhang RQ, Guo Y, He B, Zhou HM. Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer. J Cancer Res Clin Oncol. 2015 May; 141(5):901-8.
    View on PubMed
  18. Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA. Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma. Clin Cancer Res. 2014 Dec 15; 20(24):6551-8.
    View on PubMed
  19. Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov; 15(6):426-32.
    View on PubMed
  20. Okoye CC, Jablons DM, Jahan TM, Kukreja J, Cardozo S, Yom SS. Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity. Am J Clin Oncol. 2014 Aug; 37(4):350-5.
    View on PubMed

Go to UCSF Profiles, powered by CTSI